Study S001601

A Randomised, Double Blind, Placebo-controlled, Parallel-group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.

ClinicalTrials.gov record

Registration

Registration: NCT00851773
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 84
Start: 2009-02
Primary completion: 2009-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2008-006325-13; NIH:2008

Registered primary outcomes

Adverse events [at all scheduled visits (2 - 14) following screening]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.